The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians(Open Payments)
Employment- Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
Consulting or Advisory Role- Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm